Enanta Pharmaceuticals Announces Fiscal Q4 and Full-Year 2025 Financial Results
Enanta Pharmaceuticals Reports Fiscal Fourth Quarter and Full-Year 2025 Financial Results and Highlights Major Clinical Advancements Across Virology and Immunology Programs Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company…
CorriXR Therapeutics Shares Preclinical Data on CRISPR Approach to Defeat Solid Tumor Drug Resistance
CorriXR Therapeutics Announces Publication of Preclinical Data Demonstrating the Potential of CRISPR-Directed Gene Editing to Overcome Drug Resistance in Solid Tumors CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company advancing a…
Sonoma Biotherapeutics Names Stephen Dilly CEO as Jeff Bluestone Becomes Advisor
Sonoma Biotherapeutics Announces Leadership Transition as Stephen Dilly, MBBS, PhD, Becomes President and CEO; Co-founder Jeff Bluestone, PhD, Assumes Advisory Role Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company advancing engineered…
Solve Therapeutics Secures $120M to Advance Next-Generation ADC Therapies for Solid Tumors
Solve Therapeutics Raises $120 Million to Accelerate Next-Generation ADC Development for Solid Tumors Solve Therapeutics, a rapidly advancing clinical-stage biotechnology company focused on creating best-in-class antibody–drug conjugates (ADCs) for the…
Scribe Therapeutics Showcases Key ASCVD Lipid Driver Data at AHA 2025
Scribe Therapeutics Highlights Major ASCVD Lipid Insights at AHA 2025 Scribe Therapeutics Inc. (“Scribe”), a leading genetic medicines company engineering next-generation in vivo CRISPR-based treatments, unveiled a series of breakthrough…
J&J Moves to Redefine Cancer Treatment Through Halda Therapeutics Buyout
Johnson & Johnson Strengthens Oncology Leadership With $3.05 Billion Acquisition of Halda Therapeutics and Its Next-Generation RIPTAC™ Platform Johnson & Johnson (NYSE: JNJ) announced that it has entered into a…
JSR Life Sciences Reaches Definitive Agreement to Transfer Crown Bioscience to Adicon
JSR Life Sciences Announces Definitive Agreement to Transfer Crown Bioscience to Adicon Holdings, Marking a Significant Strategic Realignment in Oncology Research Services JSR Life Sciences LLC (“JSR Life Sciences”), a…
Inflammasome Therapeutics, Healey & AMG Center Launch ALS Treatment Collaboration
Inflammasome Therapeutics to Collaborate with Healey & AMG Center on New ALS Treatment Study Inflammasome Therapeutics, a clinical-stage biotechnology company advancing a new category of drug candidates known as Kamuvudines…
Flightpath Biosciences Boosts Pipeline with New Drug License, Launches New Brand Identity
Flightpath Biosciences Advances Precision Anti-Infective Strategy with New Drug License and Corporate Rebrand as Company Enters Next Phase of Growth Flightpath Biosciences, a clinical-stage biotechnology company committed to developing innovative…
Survey Finds Non–Muscle Invasive Bladder Cancer Patients Want More Dialogue in Their Care
New Survey Shows NMIBC Patients Want More Inclusive Care Conversations and Greater Awareness of Emerging Treatment Options A new national survey conducted in the United States by The Harris Poll,…
Gilead’s Bictegravir–Lenacapavir HIV Pill Meets Phase 3 ARTISTRY-1 Goal
Single-tablet regimen shows non-inferior efficacy and strong safety in virologically suppressed adults with HIV-1. Gilead Sciences, Inc. (NASDAQ: GILD) has announced encouraging topline results from its Phase 3 ARTISTRY-1 clinical…
KORU Medical Systems Reports 27% Revenue Growth in Q3 and Increases Full-Year 2025 Outlook
KORU Medical Systems Reports 27% Third Quarter Revenue Growth and Raises Full-Year 2025 Guidance KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology firm…